30 Stocks Top Picks (NOV 16-22)

Opinion about HBC-T: Nicknames it Hit By A Car like its chart. HBC is all about its real estate holdings; that's the reason you own this. Doesn't know if the current rally signals a buy. Can't predict this chart. Even consider selling it.

Opinion about MHK-N: They had a great quarter, but so did Whirlpool and the market didn't pay attention. He prefers Whirlpool.

Opinion about DOL-T: Wouldn't buy now. Has benefited from the economic uncertainty, and so valuation has come up dramatically. North of 35x PE, so risk that could contract over the long term. Wonderful business, well positioned with price points to capture a larger portion of wallets in tough times. Last conference call referenced a small impact…

Opinion about BRB-T: (A Top Pick Jun 18/18, Up 1%) Still likes it. It's well-run. They're growing their brands and they have a big opportunity to get into cannabis beverages which will be legal in Canada in October 2019. BRB is well-positioned for this and this market could be very large.

Opinion about GC-T: Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Takeover offer. Pandemic hit hard. Solid assets, but re-opening slowed. Healthy balance sheet.

Browse a daily summary of experts opinions on stocks and stock investment information.

Opinion about FANG-Q: Bought more. Great management and M&A strategy, which will add to earnings regardless of the oil price. Likes their cost control and cash flow.

Opinion about PE-N: (A Top Pick Sep 01/20, Up 56.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PE has resulted in the company being acquired by Pioneer Natural Resources. We are considering the position now closed at the last market closing price of $16.93. Combined with the previous recommendation to cover 50%, the…

Opinion about BTE-T: (A Top Pick Apr 02/24, Down 56%) Drawdown 100% connected to price of oil. More debt than average. Risk-off market. Totally fine on liquidity. Deep value, but needs oil at $65-70 to really start humming.

Opinion about VET-T: (A Top Pick Mar 15/24, Down 37%) Lately they've had success in exploration in Germany, but near-term capex to exploit that is questionable. Are hard hit, now trading at half their book value. Are paying a near-6% dividend. He's held on. He may use VET as a source of funds, but otherwise…

Opinion about SGY-T: Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research SGY is quite small at $510M, but the stock is very cheap. With a 10% dividend, a buyer (or privatization) could eliminate the dividend and use internal cash flow to pay for the whole company in about three years. But, that doesn't…

Opinion about CPG-T: Great company. Looking at the chart, big wall of resistance it just couldn't get through. Then it broke out. If you own it, hold. If it pulls back to the neckline, he'd be all over it.

Opinion about TRP-T: Defensive. Pays a 4.8% dividend. Natural gas demand will endure. No tariff worries. Data centres need power, and he doubts tariffs will impact Canadian energy supply. (Analysts’ price target is $71.18)

Opinion about ENB-T: Great income investment with its great dividend yield. Plans to expand main line and continue capex. Returning $$ to shareholders. Has become more US-based. Great story, continues to execute well, plans in place for future.

Opinion about ISC-T: Monopoly-type business. 30-year contract on Saskatchewan land registry services. Trades at ~8x EBITDA. Generates about 11% free cashflow yield. Yield is 3.5%. (Analysts’ price target is $34.00)

Opinion about CME-Q: CME Group is committed to delivering new ways to manage risk and improve efficiency. Whether that means developing product solutions to empower trading strategies, expanding access to unique data insights, seamlessly connecting siloed liquidity pools, or introducing more ways to optimize the time and capital required for world-class risk management, new opportunities…

Opinion about BAM.A-T: BN owns a percentage of BAM. BN is trading at a discount to NAV, widest discount in a long time, which is why you want to look at buying it here. Working at home has hurt BN's commercial properties. BN has raised lots of capital, great company, well run. BAM and BN…

Opinion about WIR.UN-T: (A Top Pick Jan 12/21, Up 48%) Great-managed REIT. Taken out.

Opinion about V-N: Reliable name. Vast network, trusted brand, unmatched scale. Move from cash to digital payments. Consumer spending remains pretty solid in US. Cross-border transactions remain strong. Pretty capital light, which means very strong free cashflows. About 13% annual growth rate, paying a slight premium for the name. Recently bounced off 200-day MA very nicely,…

Opinion about AAPL-Q: Has incredible gross margins. They just reported a fine quarter, but tariffs in China didn't help. The street perceives that as the last great quarter, so shares fell. Apple is trying to move production from China to India but who know how long it will take. Services revenue disappointed and a monopoly…

Opinion about MSFT-Q: He has been buying tech during this dip, in April particularly. We will eventually exit this volatility and find stability and confidence in the market again. Meta and Microsoft are some of his key holdings, and they affirmed their capex guidance--they are spending to make incredible investments over the next three years,…

Opinion about ECL-N: Good time to buy. 

Opinion about NTR-T: World's largest crop-nutrient business. Upstream production is vertically integrated with downstream retail. Gamechanger for him is that commodity price has bottomed for potash, nitrogen, and phosphate. Cash crop commodity prices are also slowly improving. Management changes. Operational changes to improve profitability. Trading at 1.1x book. Good luck tariffing potash, as the US produces…

Opinion about SYK-N: (A Top Pick Apr 10/24, Up 0.48%) Down along with the market. About 73% of revenues from US; rest is from other parts of the world, so lots of growth internationally. Very strong demographic play. Great company.

Opinion about BMY-N: She bought it because the industry has underperformed many years; they're facing several drugs coming off patent, but are developing new drugs they will bring to market. Trades under 9x PE and pays a 4.6% dividend. This industry will benefit greatly from AI.

Opinion about BIP-N: Not really affected by tariffs. In the private equity area. Probably the fastest-growing part of the business. Will continue to be quite a hot area. He prefers BN.

Opinion about SPGI-N: Very high margins, very profitable, recurring revenue. Oligopoly with Moody's. Divisions experiencing good growth. Highly scalable. Well positioned to benefit from increased capital markets activity. Long-term compounder. Yield is 0.7%. (Analysts’ price target is $601.52)

Opinion about H-T: (A Top Pick Jul 12/24, Up 11%) It broke out since mid-July but has been sideways lately. As long as the stock holds at lows around $44, fine, but if it breaks below that, there will likely be more downside.

Opinion about T-T: Below 200-day MA; also moving below 200-week MA, which is trending lower. Need interest rates to come down for this sector to do well. Yield is 7.64%, and that dividend could ease going forward. Tough space.

Opinion about BCE-T: Average down? The expectation is for a dividend cut of nearly 50% starting this month. We'll see if that happens. Technically, shares are having a rough go below both the 200-day and 200-week MAs. Earnings growth is sub-standard, even negative.So, no, he wouldn't add at this stage. At some point, things could…